NCT01504321View on ClinicalTrials.gov

Polycystic Ovary Syndrome - Improving Outcomes

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

December 31, 2015

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Moxonidine

0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months

DRUG

Placebo

Encapsulated lactose powder

Trial Locations (1)

3004

Heart Centre, Alfred Hospital, Prahran

All Listed Sponsors
lead

Baker Heart and Diabetes Institute

OTHER

NCT01504321 - Polycystic Ovary Syndrome - Improving Outcomes | Biotech Hunter | Biotech Hunter